231 related articles for article (PubMed ID: 29222264)
1. Incorporation of nonchemotherapeutic agents in pediatric acute lymphoblastic leukemia.
Silverman LB
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):259-264. PubMed ID: 29222264
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibodies and immune therapies for adult precursor B-acute lymphoblastic leukemia.
Sikaria S; Aldoss I; Akhtari M
Immunol Lett; 2016 Apr; 172():113-23. PubMed ID: 26921100
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in the treatment of acute lymphoblastic leukemia.
Rafei H; Kantarjian HM; Jabbour EJ
Leuk Lymphoma; 2019 Nov; 60(11):2606-2621. PubMed ID: 31092071
[TBL] [Abstract][Full Text] [Related]
4. New immune strategies for the treatment of acute lymphoblastic leukemia: antibodies and chimeric antigen receptors.
Advani AS
Hematology Am Soc Hematol Educ Program; 2013; 2013():131-7. PubMed ID: 24319174
[TBL] [Abstract][Full Text] [Related]
5. Future of Therapy in Acute Lymphoblastic Leukemia (ALL)--Potential Role of Immune-Based Therapies.
Kebriaei P; Poon ML
Curr Hematol Malig Rep; 2015 Jun; 10(2):76-85. PubMed ID: 25899862
[TBL] [Abstract][Full Text] [Related]
6. How should we treat a patient with relapsed Ph-negative B-ALL and what novel approaches are being investigated?
Gökbuget N
Best Pract Res Clin Haematol; 2017 Sep; 30(3):261-274. PubMed ID: 29050699
[TBL] [Abstract][Full Text] [Related]
7. Bispecific antibodies in acute lymphoblastic leukemia therapy.
Chitadze G; Laqua A; Lettau M; Baldus CD; Brüggemann M
Expert Rev Hematol; 2020 Nov; 13(11):1211-1233. PubMed ID: 33000968
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy in pediatric acute lymphoblastic leukemia.
Inaba H; Pui CH
Cancer Metastasis Rev; 2019 Dec; 38(4):595-610. PubMed ID: 31811553
[TBL] [Abstract][Full Text] [Related]
9. Humoral and cellular immunotherapy in ALL in children, adolescents, and young adults.
Hochberg J; El-Mallawany NK; Cairo MS
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S6-13. PubMed ID: 25486958
[TBL] [Abstract][Full Text] [Related]
10. Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia.
Liu D; Zhao J; Song Y; Luo X; Yang T
J Hematol Oncol; 2019 Feb; 12(1):15. PubMed ID: 30736842
[TBL] [Abstract][Full Text] [Related]
11. SOHO State of the Art Update and Next Questions: Advances in the Treatment of Adult Acute Lymphoblastic Leukemia.
Paul S; Rausch CR; Welch MA; Kantarjian HM; Jabbour EJ
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):471-479. PubMed ID: 31307896
[TBL] [Abstract][Full Text] [Related]
12. New targeted therapies for relapsed pediatric acute lymphoblastic leukemia.
Pierro J; Hogan LE; Bhatla T; Carroll WL
Expert Rev Anticancer Ther; 2017 Aug; 17(8):725-736. PubMed ID: 28649891
[TBL] [Abstract][Full Text] [Related]
13. Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia.
Rossoff J; Baggott C; Prabhu S; Pacenta H; Phillips CL; Stefanski H; Talano JA; Moskop A; Margossian SP; Verneris MR; Myers GD; Karras N; Brown PA; Qayed M; Hermiston M; Satwani P; Krupski C; Keating AK; Wilcox R; Rabik CA; Fabrizio VA; Kunicki M; Chinnabhandar V; Goksenin AY; Curran KJ; Mackall CL; Laetsch TW; Schultz LM
Blood; 2021 Nov; 138(21):2138-2142. PubMed ID: 34499715
[No Abstract] [Full Text] [Related]
14. Innovative Approaches to the Management of Acute Lymphoblastic Leukemia Across the Age Spectrum.
Curran E; Muffly L; Luskin MR
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-11. PubMed ID: 35503981
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapy paves the way for the cure of acute lymphoblastic leukaemia.
Rafei H; Kantarjian HM; Jabbour EJ
Br J Haematol; 2020 Jan; 188(2):207-223. PubMed ID: 31566728
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy in pediatric B-cell acute lymphoblastic leukemia.
Wyatt KD; Bram RJ
Hum Immunol; 2019 Jun; 80(6):400-408. PubMed ID: 30716352
[TBL] [Abstract][Full Text] [Related]
17. Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia.
Danylesko I; Chowers G; Shouval R; Besser MJ; Jacoby E; Shimoni A; Nagler A; Avigdor A
Curr Res Transl Med; 2020 Jan; 68(1):17-22. PubMed ID: 31882377
[TBL] [Abstract][Full Text] [Related]
18. The Approach to Acute Lymphoblastic Leukemia in Older Patients: Conventional Treatments and Emerging Therapies.
Fedorov VD; Upadhyay VA; Fathi AT
Curr Hematol Malig Rep; 2016 Jun; 11(3):165-74. PubMed ID: 26939921
[TBL] [Abstract][Full Text] [Related]
19. Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia.
Jabbour E; Pui CH; Kantarjian H
JAMA Oncol; 2018 Oct; 4(10):1413-1420. PubMed ID: 29931220
[TBL] [Abstract][Full Text] [Related]
20. The future of cellular immunotherapy for childhood leukemia.
Bonifant CL; Tasian SK
Curr Opin Pediatr; 2020 Feb; 32(1):13-25. PubMed ID: 31851053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
